GLP-1 medications work for both men and women, but women's metabolic health, hormonal fluctuations, and the specific challenges of perimenopause and menopause mean a gender-informed approach makes a meaningful clinical difference. Eros MD provides programs that account for the full picture.
why women differ
Women's bodies regulate weight differently than men's, and the gap widens with age. Hormonal fluctuations throughout the menstrual cycle, the metabolic shifts of perimenopause, and the sustained effects of postmenopause all create a weight management landscape meaningfully different from the male experience.
Estrogen plays a central role in fat distribution, metabolic rate, and insulin sensitivity. As estrogen declines during perimenopause and menopause, many women experience increased abdominal fat accumulation, reduced muscle mass, and greater insulin resistance, all of which make weight management more challenging through diet and exercise alone.
These are not failures of effort or discipline. They are physiological realities. GLP-1 medications address the hormonal and metabolic underpinnings of weight gain, which is precisely why they are particularly effective for women navigating hormonal transitions.
treatment options
The same weight loss medication classes available in the general program, evaluated by a physician who accounts for hormonal factors, contraceptive considerations, and menopausal status.
FDA-approved for chronic weight management. Clinical trials included women and showed consistent efficacy. Weekly injection. Average 15 percent body weight reduction.
~15 percent average body weight reduction in trials
Dual GLP-1 / GIP agonist with up to 22 percent body weight reduction in trials. FDA-approved for chronic weight management. The newest and most effective option currently available.
Up to ~22 percent average body weight reduction
Thyroid conditions are more common in women and can significantly affect weight and medication response. Screening is part of the intake when clinically indicated, often before or alongside medication therapy.
Perimenopausal women often find weight loss medications more effective when paired with progesterone or full HRT, because metabolic shifts often share hormonal drivers. We coordinate across programs.
medication comparison
GLP-1 Receptor Agonist
Dual GLP-1 / GIP Agonist
Feature
Mechanism
Avg Weight Loss
Administration
Best For
GLP-1 Receptor Agonist
GLP-1 only
~15 percent
Weekly injection
First-line, longest track record
Dual GLP-1 / GIP Agonist
GLP-1 + GIP
Up to ~22 percent
Weekly injection
Maximum efficacy, newer generation
hormonal considerations
Women's weight loss care is most effective when it accounts for more than the numbers on the scale. Hormonal context (thyroid, reproductive, perimenopausal) directly affects metabolic rate, appetite, and response to GLP-1 medications. The women who struggle most with weight are often women whose hormonal picture was never fully evaluated.
Eros MD's women's program includes physician evaluation at intake, thyroid screening when clinically indicated, GLP-1 prescribing with appropriate monitoring, coordinated care with our perimenopause and menopause programs when relevant, and ongoing provider access. A whole-system view, not a weight loss script.
GLP-1 medications can affect absorption of oral contraceptives due to slowed gastric emptying. Provider will advise on backup contraception during dose escalation.
Providers evaluate how hormonal changes are affecting weight management and may recommend complementary approaches such as HRT.
Thyroid conditions are more common in women. PCOS involves insulin resistance and weight challenges that GLP-1 medications directly address. Both are screened for as part of intake.
Questions worth asking
Clinical trial data shows GLP-1 medications are highly effective for both men and women. Some studies suggest women may experience slightly different side effect profiles, but overall efficacy evidence is strong across both sexes. Your physician tailors the program to your individual profile.
These medications can slow gastric emptying, potentially affecting oral contraceptive absorption. A backup contraceptive method is generally recommended during dose escalation and for a period after reaching maintenance dose. Your provider will give specific guidance based on your contraceptive method.
Yes. GLP-1 medications are not contraindicated by menopausal status. Many women find them particularly helpful during hormonal transitions when weight management becomes more physiologically challenging. Your provider accounts for menopausal status in your program plan.
PCOS is associated with insulin resistance and weight management challenges, and GLP-1 medications address both. Some clinical evidence supports GLP-1 use in women with PCOS. Eligibility is determined by your provider based on your full health profile.
No. GLP-1 medications are contraindicated during pregnancy. If you are pregnant, planning to become pregnant, or breastfeeding, inform your provider before starting or continuing treatment. If you become pregnant during treatment, discontinue immediately and consult your OB/GYN.